Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06708455 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT06708455 · ClinicalTrials.gov record · last posted 2026-03-19

Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma

Name: Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma — clinical trial record (NCT06708455)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 2

SponsorRapa Therapeutics LLC

Started2027-03-01

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

The protocol is a Simon's 2-stage, non-randomized, open label, multi-site, phase 2 trial for patients with advanced metastatic, recurrent and unresectable malignant melanoma that has recurred or relapsed after prior anti-PD-(L)1 therapy.

Amendment record 2 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 2 times since 2024-11-25; most recent amendment 2026-03-17. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

Trial Details

NCT Number	NCT06708455
Lead Sponsor	Rapa Therapeutics LLC
Conditions	Malignant Melanoma With Metastasis, Malignant Melanoma, Malignant Melanoma Stage IIIc, Malignant Melanoma Stage IV
Enrollment	65 participants
Start Date	2027-03-01
Primary Completion	2029-03-01 (estimated)
Study Completion	2029-09-30 (estimated)
Updated on ClinicalTrials.gov	2026-03-19